Induction of Apoptotic Cell Death in Non-Small-Cell Lung Cancer Cells by MP28 Peptide Derived from Bryopsis plumosa
Heabin Kim1, Seung-Hyun Jung1, Seonmi Jo2
1Department of Bio-Material Research, National Marine Biodiversity Institute of Korea, Seocheon 33662, Republic of Korea.
Abstract:
Marine algae are a prolific bioactive peptide source with a broad pharmacological potential. We characterized MP28, a cationic peptide isolated from the green alga Bryopsis plumosa. Structural modeling indicated a predominantly amphipathic α-helix (residues 3-16) flanked by flexible termini and stabilized by intramolecular disulfide bonds, a motif typical of membrane-active anticancer peptides. Functionally, MP28 demonstrated potent activity against non-small-cell lung cancer cell lines (A549, H460, H1299) without affecting non-tumorigenic lung fibroblasts (MRC-5). In vitro, MP28 decreased cell viability and clonogenic growth and suppressed migration and invasion in a dose-dependent manner. Flow cytometry revealed increased early/late apoptotic fractions, accompanied by caspase-9 activation, consistent with engagement of the intrinsic apoptotic pathway. In a mouse xenograft model, MP28 treatment significantly reduced tumor size compared with that of controls. Collectively, MP28 may be a potent anticancer peptide that exhibits selective cytotoxicity and low toxicity toward normal cells.
Insights
Marine algae yield MP28, a novel anticancer peptide effective against non-small-cell lung cancer cells. MP28 shows selective toxicity, reducing tumor growth in mice with minimal harm to normal cells.
Area of Science:
- Marine biotechnology
- Peptide therapeutics
- Cancer research
Background:
- Marine algae are rich sources of bioactive peptides.
- Anticancer peptides offer potential therapeutic strategies.
- MP28 is a cationic peptide from the green alga *Bryopsis plumosa*.
Purpose of the Study:
- To characterize the anticancer properties of MP28.
- To evaluate MP28's efficacy and selectivity against non-small-cell lung cancer (NSCLC).
- To investigate MP28's mechanism of action and in vivo effects.
Main Methods:
- Structural modeling of MP28.
- In vitro assays on NSCLC cell lines (A549, H460, H1299) and normal lung fibroblasts (MRC-5).
- Flow cytometry analysis and caspase-9 activation assays.
- In vivo efficacy study using a mouse xenograft model.
Main Results:
- MP28 exhibits an amphipathic α-helical structure.
- MP28 selectively reduced viability, clonogenic growth, migration, and invasion of NSCLC cells.
- MP28 induced apoptosis via the intrinsic pathway and reduced tumor size in vivo.
- MP28 demonstrated low toxicity toward normal lung fibroblasts.
Conclusions:
- MP28 is a potent anticancer peptide with selective cytotoxicity against NSCLC.
- MP28's mechanism involves inducing apoptosis and suppressing tumor progression.
- MP28 represents a promising candidate for NSCLC therapy with a favorable safety profile.
More Related Videos
09:26Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
Published on: February 20, 2015
09:18Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
Published on: December 27, 2016
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
